EXAS - イグザクト・サイエンシズ (Exact Sciences Corporation) イグザクト・サイエンシズ

 EXASのチャート


 EXASの企業情報

symbol EXAS
会社名 EXACT Sciences Corp. (イグザクト・サイエンシズ)
分野(sector) Health Care   ヘルスケア
産業(industry) Biotechnology: Commercial Physical_Biological Resarch  
業種 バイオテクノロジ―_メディカルリサ―チ   医療関連(Health Care)
概要 事業概要 イグザクト・サイエンシズ(Exact Sciences Corporation)は分子診断会社である。同社は癌の早期発見および予防に焦点を当てている。同社は結腸直腸癌および前癌の早期発見のためのCologuardと呼ばれる非侵襲的スクリーニング試験を提供する。コングルード試験はデオキシリボ核酸(DNA)および結腸直腸癌および前癌に関連するヘモグロビンバイオマーカーを検出するための多標的アプローチを利用する便ベースのデオキシリボ核酸(sDNA)スクリーニング試験である。コルグアード試験は、結腸直腸新生物に関連するDNAマーカーの定性的検出およびヒトの便における潜在性ヘモグロビンの存在を目的としている。同社は他のタイプの癌に対する追加試験の開発に焦点を当てる。同社はコンピュータ断層撮影(CT)または他のスキャンによって発見された肺結節を有する個体において、肺癌の早期発見を助けるための血液ベースのバイオマーカー試験を開発している。   イグザクト・サイエンシズは米国の癌検出製品メ―カ―。大腸癌および前癌状態の早期発見と予防に焦点を当て、非侵襲性スクリ―ニングテスト製品を開発。排便からDNAを検出し大腸癌に関わる遺伝子から癌を見つけ出す製品「Cologuard」を提供。同製品は前癌病変やポリ―プ、および大腸癌の4段階の進行度を検出する。   A leading provider of cancer screening and diagnostic tests, Exact Sciences relentlessly pursues smarter solutions providing the clarity to take life-changing action, earlier. Building on the success of Cologuard and Oncotype DX, Exact Sciences is investing in its product pipeline to take on some of the deadliest cancers and improve patient care. Exact Sciences unites visionary collaborators to help advance the fight against cancer.
本社所在地 441 Charmany Drive Madison WI 53719 USA
代表者氏名 Kevin T. Conroy ケヴィン・T・コンローイ
代表者役職名 Chairman of the Board President Chief Executive Officer 取締役会長兼最高経営責任者(CEO)
電話番号 +1 608-284-5700
設立年月日 34731
市場名 NASDAQ Small Cap
ipoyear 2001年
従業員数 1268人
url www.exactsciences.com
nasdaq_url https://www.nasdaq.com/symbol/exas
adr_tso
EBITDA EBITDA(百万ドル) -102.08500
終値(lastsale) 68.46
時価総額(marketcap) 8403727817.94
時価総額 時価総額(百万ドル) 8597.679
売上高 売上高(百万ドル) 353.17000
企業価値(EV) 企業価値(EV)(百万ドル) 828.906
当期純利益 当期純利益(百万ドル) -249.37200
決算概要 決算概要 BRIEF: For the six months ended 30 June 2018 EXACT Sciences Corporation revenues increased 82% to $193.2M. Net loss applicable to common stockholders increased 15% to $75.8M. Revenues reflect an increase in demand for the Company's products and services due to favorable market conditions. Higher net loss reflects Sales and marketing - Balancing value increase of 38% to $55.1M (expense) Interest expense increase from $104K to $15.1M (expense).

 EXASのテクニカル分析


 EXASのニュース

   Bull of the Day: Exact Sciences (EXAS) | Investing.com  2021/07/19 11:20:06 Investing.com
Stocks Analysis by Zacks Investment Research covering: EXACT Sciences Corporation, Pacific Biosciences of California, InVitae Corp, Natera Inc. Read Zacks Investment Research''s latest article on Investing.com
   Gilbert & Cook, Inc. Buys iShares Russell Top 200 ETF, Owl Rock Capital Corp, SPDR S&P ...  2021/07/13 16:38:06 GuruFocus
Related Stocks: MSFT , EMLC , CSGP , EWW , VMBS , AMD , IWL , ORCC , SLYV , ADBE , NVDA , NKE , VBR , CCK , FIVN , EXAS , PGR , PENN ,
   Canton Hathaway, LLC Buys iShares Russell 2000 ETF, Palantir Technologies Inc, Flex, Sells ...  2021/07/08 20:38:02 GuruFocus
Related Stocks: IWM , PLTR , F , CCI , TSLA , MRMD , FLEX , MSOS , EXAS , STE , FNCL , TECK , VEA , CIEN , AMD , VWO , FOCS , INTC , VONV , VONG , BNDX , BSV , PAGS , VMBS ,
   CEOs from Exact Sciences, Cisco, MGIC urge Wisconsin Legislature to OK $150M for UW engineering school  2021/06/30 16:57:48 Business Journals
Some of the most powerful executives in Wisconsin business including Kevin Conroy, Ted Kellner, Cory Nettles and Curt Culver signed a full-page newspaper advertisement urging the Wisconsin Legislature to add $150 million for a new engineering building at UW-Madison but likely wont achieve their goal during the current state-budget cycle.
   Neuroendocrine Tumors Market Development Industry Trends Key Driven Factors Segmentation And Forecast To 2021-2028||Eli Lilly, LUPIN, Exact Sciences Corporation, Pfizer and Ipsen Pharma  2021/06/30 05:39:10 OpenPR
To have a powerful business growth and success in this swiftly changing marketplace, companies must plump for Neuroendocrine Tumors Market report which benefits them by giving a broad range of information. This market survey provides key information about the
   Cancer Biomarkers Market to Garner $26,979.50 Mn by 2027 | Abbott Laboratories, Exact Sciences Corporation, Bristol-Myers Squibb Company  2021/06/25 04:28:48 OpenPR
According to the report, the global cancer biomarkers industry was estimated at $10.94 billion in 2019, and is expected to hit $26.97 billion by 2027, registering a CAGR of 11.8% from 2020 to 2027. COVID-19 scenario- Prevention of cancer by analyzing various
   Cancer Biomarker Market to reach $26,979.50 million by 2027 | Abbott Laboratories, Bio-Rad Laboratories, Inc., Bristol-Myers Squibb Company, Exact Sciences Corporation  2021/06/24 04:56:32 OpenPR
According to the report, the global cancer biomarkers industry was estimated at $10.94 billion in 2019, and is expected to hit $26.97 billion by 2027, registering a CAGR of 11.8% from 2020 to 2027. Prevalence of various types of cancers such
   EXACT Sciences Corporation (EXAS): Are Hedge Funds Right About This Stock?  2021/06/23 16:31:13 Insider Monkey
   Trends - Strong Revenue Trend Could Drive EXACT Sciences Corporation Stock To $160  2021/06/18 09:09:06 BusinessMag
Up around 2.5x from its low in March 2020, at the current price of $126 per share, we believe EXACT Sciences Corporation stock has further upside potential. EXAS, a molecular
   Silver, miners mauled after Fed turns more hawkish  2021/06/17 14:30:27 Seeking Alpha
   Merrill Lynch Stick to Their Buy Rating for Exact Sciences Corp. By Investing.com  2021/05/05 05:25:01 Investing.com
Merrill Lynch Stick to Their Buy Rating for Exact Sciences Corp.
   Cologuard® CRC Screening Test Most Cost-Effective Test in Medically Underserved Alaska Native People  2021/04/28 10:00:00 Benzinga
MADISON, Wis. , April 28, 2021 /PRNewswire/ -- Exact Sciences (NASDAQ: EXAS ) today announces study results published in Mayo Clinic Proceedings showing that Cologuard (mt-sDNA) is the most cost-effective colorectal cancer (CRC) screening option in the Alaska Native population, as compared to colonoscopy and the fecal immunochemical test (FIT), for a wide range of adherence scenarios. According to the model, Cologuard produced the highest number of quality adjusted life years (QALYs) gained and the largest reduction in CRC incidence. 1 Colorectal cancer is the second leading cause of cancer death for men and women in the United States , 2 in part because many cancers go undetected until later stages when treatment is less effective. 3 Alaska Native (AN) people have among the nation's highest reported incidence rates for CRC, at 89.0 per 100,000 people compared to 45.7 per 100,000 people for the entire United States . 4 Despite the clear need, screening AN people presents significant challenges, such as lower sensitivity for cancer and pre-cancer with other stool-based tests and obstacles around getting people from their remote homes to healthcare facilities, which requires significant time, expense, and support personnel. 5 The Cologuard test provides a path to overcome these barriers by offering patients a CRC screening test that allows them to collect their sample at home.
   Ark Funds, Illumina Invest In SomaLogic SPAC Deal: What Investors Should Know  2021/03/29 15:16:06 Benzinga
A leader in the proteomics field is going public with a SPAC deal announced Monday. The SPAC Deal: SomaLogic announced a SPAC deal with CM Life Sciences II Inc (NASDAQ: CMIIU ), valuing the company at $1.2 billion. A $375 million PIPE on the SPAC merger includes investments from SoftBank Group Corp (OTC: SFTBY ), T. Rowe Price, Illumina, Inc. (NASDAQ: ILMN ), Novartis AG (NYSE: NVS ) and accounts advised by Ark Invest. Kevin Conroy, the CEO of EXACT Sciences Corporation (NASDAQ: EXAS ) will join the board of directors after the merger is complete. Current shareholders of CM Life Sciences II will own 14% of the company after the merger. PIPE investors will own 20% of the company after the merger. About SomaLogic: Using … Full story available on Benzinga.com
   Jamie Foxx, Stand Up To Cancer And Exact Sciences Launch PSA To Increase Awareness Of Colorectal Cancer  2021/03/17 16:30:00 PR Newswire
LOS ANGELES, March 17, 2021 /PRNewswire-HISPANIC PR WIRE/ -- Academy Award® winner Jamie Foxx has joined Stand Up To Cancer® (SU2C) and Exact Sciences for a new public service announcement (PSA), which raises awareness about colorectal cancer screenings, early detection and prevention,…
   Mad Money Lightning Round: Beyond Meat, Teladoc Health, More  2021/03/16 12:00:00 The Street
Jim Cramer's bullish on Beyond Meat, Teladoc, Exact Sciences and more.

 関連キーワード  (バイオテクノロジ―_メディカルリサ―チ 米国株 イグザクト・サイエンシズ EXAS Exact Sciences Corporation)

 twitter  (公式ツイッターやCEOツイッターなど)